Cash and Cash Equivalents
Cash and cash equivalents at June 30, 2011, were $3.3 million, compared to $4.1 million at December 31, 2010. During the second quarter, cash was used to fund existing operations and sales growth. As a result of increases in revenues, accounts receivable balances grew from $4.7 million at December 31, 2010 to $6.4 million at June 30, 2011.
Second Quarter Corporate Development Highlights
Company Announces Search for CEO – On July 22, 2011, Kathleen Danenberg stepped down from the position of CEO and was appointed by the Board of Directors to serve as Founder and Executive Scientific and Technology Officer of the Company to focus her attention on the Company’s scientific research and development activities. Denise McNairn, Vice President, General Counsel and Secretary, will serve as the Company’s CEO on an interim basis, while the Company searches for a permanent successor to Ms. Danenberg.To facilitate the search for a new CEO, the Board has engaged CTPartners, a leading executive search firm, to assist in identifying qualified candidates. New ResponseDX™ Test Panel Launched – In June 2011, Response Genetics announced the nation-wide availability of its newest test panel, ResponseDX: Melanoma™, a proprietary, PCR-based diagnostic test that quantitatively analyzes mutations in the BRAF gene – a key component in cell signaling and growth. Such information can help physicians make treatment decisions for patients with this aggressive form of skin cancer. Presentation at ASCO – The Company presented five abstracts at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data highlighted clinical results in non-small cell lung cancer (NSCLC) and esophageal cancer and novel approaches to improve cancer care . All studies presented used technology developed by Response Genetics to isolate RNA from formalin-fixed, paraffin-embedded (FFPE) archived tissue for quantitative RT-PCR analysis of gene expression. Improved Capital Position – The Company agreed to sell 1,175,512 shares of its common stock, at a price of $1.99 per share in a registered direct public offering to certain institutional investors. Net proceeds of approximately $2.2 million were received from the sale, after deducting estimated offering expenses. The closing of the offering took place on May 6, 2011. In addition, the Company has secured a $3 million line of credit with Silicon Valley Bank. Second Quarter Gross Margin and Revenue per Case – Gross margin for the second quarter of 2011 was 58.2 percent compared to 54.4 percent for the first quarter of 2011. For the second quarter of 2011, the average revenue per case was $1,350 compared to $1,380 in the first quarter of 2011. Gross margin is defined as revenues less cost of revenues. About Response Genetics, Inc. Response Genetics Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999, and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com. Forward-Looking Statement Notice Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to successfully announce its second quarter 2011 financial statements and to continue to execute on its business strategy and operations, ths, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
RESPONSE GENETICS, INC.
CONSOLIDATED BALANCE SHEETS
| June 30,
|Cash and cash equivalents||$||4,120,074||$||3,321,937|
|Prepaid expenses and other current assets||941,981||567,686|
|Total current assets||9,795,753||10,276,209|
|Property and equipment, net||805,817||1,307,513|
|LIABILITIES, COMMON STOCK CLASSIFED OUTSIDE OF STOCKHOLDERS’ EQUITY (DEFICIT) AND STOCKHOLDERS’ EQUITY (DEFICIT)|
|Accrued payroll and related liabilities||1,271,037||1,208,836|
|Total current liabilities||5,922,214||4,673,104|
|Deferred revenue, net of current portion||100,070||32,006|
|Commitments and contingencies|
|Common stock classified outside of stockholders’ equity (deficit)||7,854,682||7,854,682|
|Stockholders’ equity (deficit)|
|Common stock, $0.01 par value; 50,000,000 shares authorized; 15,297,183 and 18,693,368 shares issued and outstanding at December 31, 2010 and June 30, 2011, respectively||122,942||134,327|
|Additional paid-in capital||40,612,785||43,283,397|
|Accumulated other comprehensive loss||(193,960||)||(232,397||)|
|Total stockholders’ equity (deficit)||(3,275,396)||(976,070||)|
|Total liabilities and stockholders’ equity (deficit)||$||10,601,570||$||11,583,722|
RESPONSE GENETICS, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Three Months
Ended June 30,
| Six Months
Ended June 30
|Cost of revenue||2,520,255||2,800,904||4,654,063||5,501,826|
|Selling and marketing||1,422,788||1,417,460||2,771,705||2,856,586|
|General and administrative||1,735,579||2,347,217||3,467,100||4,224,562|
|Research and development||388,046||221,546||960,230||385,888|
|Total operating expenses||6,066,668||6,787,127||11,853,098||12,968,862|
|Other income (expense):|
|Loss before provision for income taxes||(425,038||)||(87,344||)||(2,518,328||)||(344,235||)|
|Provision for income taxes||—||—||1,256|
|Unrealized gain (loss) on foreign currency translation||(1,021||)||(15,313||)||(13,442||)||(15,313||)|
|Total comprehensive loss||$||(426,059||)||$||(102,657||)||$||(2,533,026||)||$||(359,548||)|
|Net loss per share — basic and diluted||$||(0.02||)||$||(0.00||)||$||(0.15||)||$||(0.02||)|
|Weighted-average shares — basic and diluted||18,302,532||18,699,898||17,256,471||18,699,898|
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.